Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.
Ruth D. Williams, MD, Chief Medical Editor, on the debut of a new EyeNet section.
In this video, Eric Rosenberg, DO, MScEng, showcases how technology can augment surgical procedures such as MIGS in real-world applications. He demonstrates how visualization with…
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
This study assessed the impact of race and ethnicity on longitudinal test variability and time to detect glaucoma progression using standard automated perimetry (SAP) and…
Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accesse d if ad-blocking software is activated. In order…
Stay connected with NEI! Find out how to contact NEI staff for eye health information, media inquiries, and grant application assistance.
Wills Eye Resident Series : A patient presents with decreased vision after an injury , p. 62 medicare Q & A 2024 Reimbursement Update Wills…
Chronic anterior uveitis (CAU) is the most common type of pediatric uveitis, frequently associated with juvenile idiopathic arthritis (JIA). The introduction of adalimumab has improved…
This magazine has been unique in that it was the first and only publication focusing solely on presbyopia for both ophthalmologists and optometrists.